Meeting
2021 ASCO Annual Meeting
Relationship between DICER1 mutations and immunotherapy biomarkers in solid tumors.
Authors
Jie Gao
The Department of Hepatobillary Surgery，Peking University People's Hospital, Beijing, China
Jie Gao , Xia You , Taiyan Guo , Qin Zhang , Qianqian Duan , Chuang Qi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2603)
DOI
10.1200/JCO.2021.39.15_suppl.2603
Abstract #
2603
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A pan-cancer analysis of P21 activated kinase (PAK) family genes as potential biomarkers for immune checkpoint therapy.
First Author: Sun Gang
Poster
2021 ASCO Annual Meeting
Prevalence of hyperprogressive disease (HPD) mutations and correlations to immune-related biomarkers in a large pan-cancer Chinese cohort.
First Author: Shengli Yang
Poster
2021 ASCO Annual Meeting
A pan-cancer analysis of MUC family genes as potential biomarkers for immune checkpoint therapy.
First Author: Yang Li
Poster
2018 ASCO Annual Meeting
Association of CDKN2A gene alteration with high expression of PD-L1.
First Author: Yan Zhang